This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Paroxetine
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW HIGH
No MDD or anxiety diagnosis in this archetype. If an SSRI ever becomes indicated, escitalopram (cleanest profile) or sertraline (modest activation, lowest CYP burden) are better-tolerated first-line choices. Paroxetine's anticholinergic burden, prominent weight gain, pronounced sexual dysfunction, severe withdrawal syndrome, and largest CYP2D6 interaction surface make the entry/exit cost much higher than peer SSRIs without offsetting efficacy advantage (Cipriani 2018 mid-tier efficacy, worst acceptability of common SSRIs).
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload, MMA athlete + business owner (this-archetype) | SKIP-FOR-NOW | No psychiatric indication. Anticholinergic burden + sedation are anti-cognitive; weight gain and sexual dysfunction are anti-athletic; severe withdrawal raises entry/exit cost. If anxiety or depression became indicated, escitalopram (cleanest profile, fewest interactions) or sertraline (lowest CYP burden, modest activation) are first-line. |
30-50, executive maintenance | SKIP-FOR-NOW | unless clinical indication. If SSRI needed, prefer escitalopram or sertraline. |
50+, mild cognitive decline | SKIP-PERMANENT | for cognition (anticholinergic dementia signal — Coupland 2019). Avoid in elderly when alternatives exist. |
Anxiety-prone | SKIP-FOR-NOW | relative to escitalopram/sertraline. Paroxetine is FDA-approved for GAD/panic/SAD and effective, but acceptability burden makes it a third-line SSRI choice. |
High athletic load, tested status | SKIP-FOR-NOW | Not on WADA prohibited list, but weight gain, sexual dysfunction, anticholinergic cognitive load, and severe discontinuation syndrome are unfavorable for athletic optimization. |
Sleep-disordered | OPTIONAL | Sedating profile sometimes helpful for sleep onset; but disrupts REM and contributes to next-day sluggishness. |
Recovery-focused (post-injury) | NOT-RELEVANT | — |
Strength/anabolic-focused | SKIP-PERMANENT | Worst weight gain among SSRIs (largely fat); reduces libido; serum prolactin elevation possible. |
Postmenopausal women with vasomotor symptoms (Brisdelle) | OPTIONAL | only non-hormonal Rx for moderate-to-severe hot flashes. |
- ★20-30, brain-priority, high cognitive workload, MMA athlete + business owner (this-archetype)SKIP-FOR-NOW
No psychiatric indication. Anticholinergic burden + sedation are anti-cognitive; weight gain and sexual dysfunction are anti-athletic; severe withdrawal raises entry/exit cost. If anxiety or depression became indicated, escitalopram (cleanest profile, fewest interactions) or sertraline (lowest CYP burden, modest activation) are first-line.
- 30-50, executive maintenanceSKIP-FOR-NOW
unless clinical indication. If SSRI needed, prefer escitalopram or sertraline.
- 50+, mild cognitive declineSKIP-PERMANENT
for cognition (anticholinergic dementia signal — Coupland 2019). Avoid in elderly when alternatives exist.
- Anxiety-proneSKIP-FOR-NOW
relative to escitalopram/sertraline. Paroxetine is FDA-approved for GAD/panic/SAD and effective, but acceptability burden makes it a third-line SSRI choice.
- High athletic load, tested statusSKIP-FOR-NOW
Not on WADA prohibited list, but weight gain, sexual dysfunction, anticholinergic cognitive load, and severe discontinuation syndrome are unfavorable for athletic optimization.
- Sleep-disorderedOPTIONAL
Sedating profile sometimes helpful for sleep onset; but disrupts REM and contributes to next-day sluggishness.
- Recovery-focused (post-injury)NOT-RELEVANT
- Strength/anabolic-focusedSKIP-PERMANENT
Worst weight gain among SSRIs (largely fat); reduces libido; serum prolactin elevation possible.
- Postmenopausal women with vasomotor symptoms (Brisdelle)OPTIONAL
only non-hormonal Rx for moderate-to-severe hot flashes.
▸ Subjective experience (deep)
Onset: First 1-2 weeks bring drowsiness/sedation (more sedating than fluoxetine/sertraline), nausea, dry mouth, dizziness, headache. Early weeks may show activation/anxiety paradox (especially in panic disorder — start low). Class-typical emotional blunting and sexual dysfunction tend to be more pronounced than with escitalopram or sertraline. Weight gain is the most reliable long-term complaint — paroxetine is consistently the worst SSRI for weight gain in head-to-head comparisons (likely a combination of anticholinergic effect on satiety, antihistaminergic-like sedation, and 5-HT2C-mediated metabolic effects).
Discontinuation: even short missed doses (24-48 hours) can produce brain zaps (paresthesia-like electrical sensations in the head with eye movement), dizziness, flu-like symptoms, irritability, vivid dreams, hyperarousal, and "rebound" anxiety. Properly tapering off paroxetine often requires 8-16+ weeks, sometimes via compounded micro-doses or oral suspension below the 10 mg tablet floor.
▸ Tolerance + cycling deep dive
- Tolerance: Therapeutic effect generally maintained; "poop-out" possible at 1-3 years requiring switch.
- Not cycled — chronic daily use for clinical indication.
- Reset protocol: N/A.
▸ Stacking deep dive
Synergistic with
- CBT / exposure therapy: Combination outperforms either alone for OCD, panic, PTSD, SAD.
Avoid stacking with
- MAOIs (phenelzine, tranylcypromine, selegiline >10 mg, moclobemide, linezolid, methylene blue): Serotonin syndrome — fatal. 14-day washout each direction.
- Tramadol, meperidine, MDMA, 5-HTP, St John's wort, triptans: additive serotonergic load.
- Tamoxifen: CYP2D6 inhibition reduces conversion to active endoxifen → increased breast cancer mortality (Kelly 2010 BMJ population-level signal). Switch to escitalopram, citalopram, or venlafaxine in breast cancer survivors.
- Pimozide, thioridazine: Contraindicated per label (CYP2D6 → QT/arrhythmia).
- Codeine, hydrocodone, oxycodone, tramadol (when used for analgesia): CYP2D6 inhibition blunts conversion to active metabolites; analgesic efficacy reduced.
- Atomoxetine, risperidone, aripiprazole, haloperidol, TCAs, metoprolol: CYP2D6 substrate accumulation.
- NSAIDs, aspirin, warfarin: GI bleed/anticoagulant additive risk via SSRI platelet effect.
- Anticholinergics (diphenhydramine, oxybutynin, TCAs): additive anticholinergic burden — paroxetine itself has the highest of the SSRI class.
Neutral / safe co-administration
Most supplements; magnesium, omega-3, vitamin D are fine. Caution with high-dose 5-HTP (theoretical serotonin excess).
▸ Drug interactions deep dive
Worst interaction profile of the SSRI class along with fluoxetine. Strong CYP2D6 inhibitor (potent), mild CYP3A4 effect. Watch for any drug requiring CYP2D6 activation (codeine, tramadol, tamoxifen) or CYP2D6 clearance (atomoxetine, risperidone, metoprolol, TCAs).
▸ Pharmacogenomics
Paroxetine is itself a CYP2D6 substrate but also a strong CYP2D6 inhibitor, which means it self-saturates and reduces the impact of CYP2D6 phenotype on its own clearance. Where genotyping helps is for the interaction layer — CYP2D6 ultra-rapid metabolizers may compensate partially for paroxetine's inhibition of substrate drugs. CYP2D6 testing has limited routine clinical utility for paroxetine dosing itself.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Rx (psychiatrist/PCP) | Pharmacy | $4-25/mo generic | high | Standard. Telehealth options widely available. Brisdelle 7.5 mg branded only. |
▸ Biomarkers to track (deep)
- Baseline: PHQ-9, GAD-7, body weight, body composition, sodium, LFTs, lipid panel, BP, HR, sexual function self-report, suicide screen. CYP2D6 genotype if available (informs comedication risk more than paroxetine itself).
- During use: PHQ-9 / GAD-7 q4-6 weeks early; sodium at 2 + 8 weeks (especially elderly); body weight monthly (paroxetine weight-gain signal); sexual function check at 6-12 weeks; lipid panel at 6 months; BP/HR routinely.
- Post-cycle (taper): Reassess withdrawal symptoms weekly during taper; PHQ-9 q3 months after discontinuation for relapse.
▸ Controversies / open debates Live debate
- Study 329 (paroxetine adolescent depression): Original Keller 2001 GSK paper claimed paroxetine efficacious and safe for adolescent MDD. Le Noury 2015 BMJ RIAT reanalysis (Restoring Invisible and Abandoned Trials initiative) demonstrated paroxetine was no more effective than placebo and carried increased suicidality. Landmark research-integrity case. GSK paid $3 billion settlement (2012, partly tied to Paxil pediatric marketing) — one of the largest healthcare fraud settlements in US history.
- Pregnancy/cardiac malformations: Paroxetine first-trimester exposure → atrial/ventricular septal defects above background. Black box warning. Magnitude of effect vs other SSRIs debated, but consensus is to avoid in early pregnancy when alternatives exist.
- Discontinuation syndrome severity: Fava 2018 systematic review documents paroxetine as carrying the highest discontinuation burden of SSRIs. Some psychiatrists argue patient counseling about taper has historically been inadequate.
- Anticholinergic dementia signal: Coupland 2019 JAMA Intern Med cohort suggests cumulative anticholinergic exposure (including paroxetine) correlates with elevated dementia risk in elderly. Causality vs confounding (depression itself a dementia risk factor) debated.
- Tamoxifen interaction magnitude: Kelly 2010 BMJ showed real-world breast cancer mortality increase. Some later studies smaller effect; clinical consensus is to avoid the combination when alternative SSRIs exist.
- PSSD (post-SSRI sexual dysfunction): Persistent dysfunction after discontinuation — reported across SSRI class but paroxetine over-represented in case series. Disputed prevalence, likely <1%.
▸ Verdict change log
- 2026-05-10 — Initial verdict: SKIP-FOR-NOW for the 20yo MMA + business owner archetype. No clinical indication; if SSRI ever required, escitalopram or sertraline preferred over paroxetine on tolerability, withdrawal, and CYP-interaction grounds.
▸ Open questions / gaps Open
Whether the anticholinergic dementia signal is causal vs confounded by depression; long-term real-world weight-gain magnitude under modern dosing; whether modern slow-taper protocols (compounded micro-doses) actually reduce withdrawal burden in head-to-head trials; PSSD prevalence post-paroxetine vs other SSRIs.
References
PMID 29477251
Cipriani 2018 Lancet network meta-analysis of 21 antidepressants.
View StudyPMID 26397451
Fava 2018 systematic review of SSRI discontinuation syndrome.
View StudyPMID 11437014
Keller 2001 original Study 329 (later reanalyzed).
View StudyPMID 9210754
Steiner 1997 PRIDE study (premenstrual dysphoria).
View StudyPMID 9292832
Modell 1997 SSRI sexual dysfunction comparative ranking.
View StudyPMID 31233099
Coupland 2019 JAMA Intern Med anticholinergic dementia risk.
View StudyPMID 20142325
Kelly 2010 BMJ paroxetine + tamoxifen breast cancer mortality.
View StudyPMID 8253716
Black 1993 paroxetine discontinuation syndrome.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.